πŸ“ˆ Jumpstart Signal Watchlist β€” August 12, 2026

πŸš€ Growth ($5-$20)

# Ticker Signal Industry Score (100) Q+E+S+B Price Change RSI 3yr High
1 BCRX1 πŸ“Œ MONITOR Biological Products 57 (28+10+9+10) $10.59 +2.5% 66 $11.19
Screening Criteria ↓

βš–οΈ Momentum ($20-$100)

# Ticker Signal Industry Score (100) Q+E+S+B Price Change RSI 3yr High
1 CON9 πŸ“Œ MONITOR Specialty Outpatient Facilit... 67 πŸŽ“ (56+2+9+0) $34.54 +5.5% 67 $34.54
2 ZD πŸ“Œ MONITOR Telegraph & Other Communicat... 62 (50+2+10+0) $54.94 +2.6% 58 $71.99
3 CCSI2 πŸ“Œ MONITOR Prepackaged Software 62 (43+0+9+10) $37.94 +3.7% 56 $38.76
4 DINO2 πŸ“Œ MONITOR Pipelines (Except Natural Gas) 60 (53+0+7+0) $87.93 +1.5% 58 $92.44
5 KFRC πŸ“Œ MONITOR Help Supply Services 60 (50+0+10+0) $57.71 +1.1% 57 $73.41
Screening Criteria ↓

πŸ† SPOTLIGHT   |   βœ… OPPORTUNITY   |   πŸ“Œ MONITOR

πŸ“‘ Movers on Our Radar

How much each stock moved from its opening price to its closing price on 2026-08-12, among the stocks that passed our Stage 1 screen. This is not a market-wide list.

πŸš€ Growth β€” Analysis

BCRX πŸ“Œ MONITOR - BioCryst Pharmaceuticals, Inc.
Score: 57/100 (28+10+9+10) Price: $10.59 Chg: +2.5% RSI: 66 Vol: 3.9M 3yr High: $11.19

🏒 What they do: BioCryst Pharmaceuticals is a biotechnology company that develops and commercializes medicines for hereditary angioedema (HAE) and other rare diseases. Its key products include ORLADEYO for preventing HAE attacks and RAPIVAB for treating influenza, and it is also advancing additional rare-disease drug candidates.
- 🎯 Current $10.59 is 5% below 3yr high $11.19 Β· ⏳ SMA200 $8.32 (current price $10.59 is above) Β· πŸ’° Market Cap $2.7B
- BCRX shows decent technicals supported by positive sentiment.

πŸ’Ž Quality (Q): 28/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1400% (>20%); Revenue growth 34% (>15%).
⏰ Entry (E): 10/20
- πŸ”” Strong above EMA21 (10.4%)
- πŸ”” Strong above EMA50 (12.2%)
- πŸ”” SMA20/SMA50 bullish crossover
- πŸ“ˆ RSI at 66 showing strength
- ⚠️ SMA20/SMA50 bearish crossover
πŸ“’ Sentiment (S): 9/10
- πŸ—žοΈ News sentiment is positive.
βœ… BioCryst Pharmaceuticals Q2 Earnings Call Highlights β€” Yahoo Finance.
πŸ€– BioCryst reported Q2 results with ORLADEYO revenue up 10% year over year and noted the start of shipments for its pediatric oral-pellet formulation. The article is also supportive because the company maintained its 2026 ORLADEYO outlook while highlighting clinical progress in navenibart.
βœ… BioCryst Q2 2026 slides: HAE portfolio drives beat, guidance raised β€” Investing.com.
πŸ€– This article says BioCryst's Q2 results beat Wall Street expectations and that the company raised its full-year revenue outlook. Guidance increases and a stronger-than-expected quarter are typically positive for the stock.
βšͺ️ RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating β€” Yahoo Finance.
πŸ€– RBC kept an Outperform rating but trimmed its price target from $14 to $13. That is mixed-to-neutral because the target was lowered, though the broker still remains constructive on the shares.
🍭 Bonus (B): 10/10 β€” Biological Products (Biotech sector)

βš–οΈ Momentum β€” Analysis

CON πŸ“Œ MONITOR - Concentra Group Holdings Parent, Inc.
Score: 67/100 (56+2+9+0) Price: $34.54 Chg: +5.5% RSI: 67 Vol: 864K 3yr High: $34.54

🏒 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 At/above 3yr high $34.54 (current $34.54) Β· ⏳ SMA200 $23.86 (current price $34.54 is above) Β· πŸ’° Market Cap $4.4B
- CON shows decent technicals supported by positive sentiment.

πŸ’Ž Quality (Q): 56/60
- 🏦 Low drawdown (13.6% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- πŸ”” Strong above EMA21 (7.9%)
- πŸ”” Strong above EMA50 (14.4%)
- πŸ“ˆ RSI at 67 showing strength
πŸ“’ Sentiment (S): 9/10
- πŸ—žοΈ News sentiment is positive.
βœ… Concentra Group Holdings Parent, Inc. Announces Results For Its Second Quarter Ended June 30, 2026, Declares Cash Dividend and Raises Full-Year 2026 Guidance β€” Yahoo Finance / Business Wire.
πŸ€– Concentra reported stronger-than-expected Q2 2026 results, with revenue up 10.0% year over year, adjusted EBITDA up 22.5%, and adjusted EPS up about 40%. Management also raised full-year 2026 guidance and declared a cash dividend, both typically supportive for the stock.
βœ… Concentra Q2 2026 slides: margin surge drives guidance raise β€” Investing.com.
πŸ€– The article highlights expanding margins and a higher full-year outlook after Q2 2026 results, which suggests improving operating momentum. A guidance increase is generally favorable for shares.
βšͺ️ Concentra Group Holdings Parent (CON) Earnings Date, ... β€” MarketBeat.
πŸ€– This page primarily summarizes the already-reported Q2 earnings release and consensus beat, but it is mostly an earnings reference page rather than fresh news. The underlying results are positive, though the page itself adds little new market-moving information.
🍭 Bonus (B): 0/10 β€” Specialty Outpatient Facilities

ZD πŸ“Œ MONITOR - Ziff Davis, Inc.
Score: 62/100 (50+2+10+0) Price: $54.94 Chg: +2.6% RSI: 58 Vol: 833K 3yr High: $71.99

🏒 What they do: Ziff Davis is a digital media and internet company that operates a portfolio of online brands and services across technology, shopping, gaming, entertainment, health and wellness, connectivity, cybersecurity, and marketing technology.
- 🎯 Current $54.94 is 24% below 3yr high $71.99 Β· ⏳ SMA200 $40.97 (current price $54.94 is above) Β· πŸ’° Market Cap $1.9B
- ZD shows decent technicals supported by positive sentiment.

πŸ’Ž Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 2668% (>20%); ROE 29% (>15%); Low LT D/E 0.39 (<1.0); Near-high ROE setup (52wk high + ROE).
πŸ“’ Sentiment (S): 10/10
- πŸ—žοΈ News sentiment is positive.
βœ… Ziff Davis Reports Second Quarter 2026 Financial Results β€” Yahoo Finance / Business Wire.
πŸ€– Ziff Davis beat earnings expectations and completed the $1.2 billion sale of its Connectivity business, which strengthened the balance sheet and supported capital returns. Revenue declined year over year, but the earnings beat and large divestiture are generally supportive for the stock.
βœ… Ziff Davis Q2 2026 Earnings Call Summary β€” Yahoo Finance.
πŸ€– The summary highlights the completed Connectivity sale, a large share-repurchase program, and improving revenue trends in parts of the business. Those factors are favorable for investor sentiment despite ongoing top-line pressure.
βœ… Ziff Davis Q2 Earnings Call Highlights β€” MarketBeat.
πŸ€– The article notes that adjusted EPS rose 13.2% and free cash flow doubled, which offset ongoing weakness in search-driven advertising. The combination of better per-share profitability and strong cash generation is positive for the stock.
🍭 Bonus (B): 0/10 β€” Telegraph & Other Communications

CCSI πŸ“Œ MONITOR - Consensus Cloud Solutions, Inc.
Score: 62/100 (43+0+9+10) Price: $37.94 Chg: +3.7% RSI: 56 Vol: 168K 3yr High: $38.76

🏒 What they do: Consensus Cloud Solutions, Inc. (CCSI) is a leading provider of digital cloud faxing services and interoperability solutions, primarily through a SaaS platform that enables secure faxing via email, web portals, APIs, and mobile apps.
- 🎯 Current $37.94 is 2% below 3yr high $38.76 Β· ⏳ SMA200 $28.15 (current price $37.94 is above) Β· πŸ’° Market Cap $696M
- CCSI shows decent technicals supported by positive sentiment.

πŸ’Ž Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 34% (>20%); ROE 228% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.23 (<1.5).
πŸ“’ Sentiment (S): 9/10
- πŸ—žοΈ News sentiment is positive.
βœ… Consensus Cloud Solutions, Inc. Reports Second Quarter 2026 Results; Reaffirms Full Year 2026 and Releases Q3 2026 Guidance; Increases Stock Buyback Program to $200 Million β€” Business Wire.
πŸ€– CCSI reported Q2 2026 revenue of $91.4 million, up 4.1% year over year, and raised its stock buyback program to $200 million. The company also reaffirmed full-year 2026 guidance and issued Q3 guidance, which is generally supportive for the stock.
βœ… Consensus Cloud Solutions earnings beat by $0.02, revenue topped estimates β€” Investing.com.
πŸ€– CCSI reported Q2 EPS of $1.49 versus the $1.47 estimate and revenue of $91.36 million versus the $89.22 million consensus. Beating both profit and sales expectations is typically positive for the stock.
βšͺ️ Consensus Q2 2026 presentation: revenue beats, shares fall 5.7% β€” Investing.com.
πŸ€– The article says CCSI beat analyst expectations on revenue and earnings, and highlighted record corporate-channel revenue and stronger free cash flow. However, it also notes the stock fell after hours because management left full-year guidance unchanged, making the market reaction mixed.
🍭 Bonus (B): 10/10 β€” Prepackaged Software (Technology sector)

DINO πŸ“Œ MONITOR - HF Sinclair Corporation
Score: 60/100 (53+0+7+0) Price: $87.93 Chg: +1.5% RSI: 58 Vol: 2.4M 3yr High: $92.44

🏒 What they do: HF Sinclair Corporation (DINO) is an independent energy company that operates refineries across the mid-continent, Southwest, Rocky Mountain regions, and Pacific Northwest in the United States, producing and marketing gasoline, diesel fuel, jet fuel, renewable diesel, specialty lubricants, chemicals, and asphalt.
- 🎯 Current $87.93 is 5% below 3yr high $92.44 Β· ⏳ SMA200 $61.56 (current price $87.93 is above) Β· πŸ’° Market Cap $19.6B
- DINO shows decent technicals supported by positive sentiment.

πŸ’Ž Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 348% (>20%); Revenue growth 53% (>15%); ROE 19% (>15%); Low LT D/E 0.27 (<1.0).
πŸ“’ Sentiment (S): 7/10
- πŸ—žοΈ News sentiment is positive (mixed coverage).
βœ… HF Sinclair Reports 2026 Second Quarter Results and Announces Increase in Regular Cash Dividend β€” Yahoo Finance / Business Wire.
πŸ€– HF Sinclair reported sharply higher Q2 2026 earnings and adjusted earnings that substantially beat prior-year results, while also raising its quarterly dividend by 5%. The strong profit improvement and higher shareholder payout are favorable for $DINO.
βœ… HF Sinclair Announces Strategic Transformation, Including Plans to Pursue A Separation of Lubricants & Specialties and Planned Retirement of its Canadian Base Oil Refining Assets β€” Yahoo Finance / Business Wire.
πŸ€– The company announced a strategic restructuring plan to separate its Lubricants & Specialties business into a new independent public company. Investors often view portfolio simplification and capital reallocation plans as potentially value-accretive for $DINO.
❌ HF Sinclair stock downgraded to Sell by Freedom Broker ... β€” Investing.com.
πŸ€– Despite acknowledging strong Q2 results, the article emphasizes a downgrade to Sell and warns about valuation after a sharp stock run-up. The downgrade is a negative signal for $DINO sentiment.
βšͺ️ Is HF Sinclair (DINO) Recasting Its Leadership to Balance ... β€” Yahoo Finance.
πŸ€– This article discusses leadership changes and frames them in the context of the upcoming earnings report, but it does not provide material new operating results or a clear rating/action. The impact on $DINO is therefore neutral based on the information shown.
🍭 Bonus (B): 0/10 β€” Pipelines (Except Natural Gas)

KFRC πŸ“Œ MONITOR - Kforce, Inc.
Score: 60/100 (50+0+10+0) Price: $57.71 Chg: +1.1% RSI: 57 Vol: 158K 3yr High: $73.41

🏒 What they do: Kforce, Inc. is a professional staffing and solutions company that connects businesses with talent in technology and finance & accounting. It provides temporary staffing, direct-hire placement, and project-based consulting/managed solutions to help clients fill specialized roles and support business and digital transformation needs.
- 🎯 Current $57.71 is 21% below 3yr high $73.41 Β· ⏳ SMA200 $37.15 (current price $57.71 is above) Β· πŸ’° Market Cap $4.2B
- KFRC shows decent technicals supported by positive sentiment.

πŸ’Ž Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 24% (>20%); ROE 30% (>15%); Low LT D/E 0.00 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 0/20
- πŸ”” VWMA trending up (5 consecutive days)
πŸ“’ Sentiment (S): 10/10
- πŸ—žοΈ News sentiment is positive.
βœ… UBS Raises Price Target on Kforce to $59 From $47, Maintains Neutral Rating β€” MT Newswires.
πŸ€– UBS lifted its price target on KFRC, which is generally supportive for the stock even though the firm kept a Neutral rating. A higher target suggests improved valuation expectations after recent operating results.
βœ… Kforce Inc. Q2 2026 Earnings Call Summary - Yahoo Finance β€” Yahoo Finance.
πŸ€– The summary highlights a positive revenue inflection, stronger Technology business growth, and improving margins in Q2 2026. Those details indicate better operating momentum, although the company also noted year-to-date negative operating cash flow.
βœ… Kforce Inc (KFRC) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Margin Expansion β€” Yahoo Finance.
πŸ€– Kforce reported higher revenue, EPS growth, and gross margin expansion, while also issuing Q3 revenue and EPS guidance above prior-quarter levels. The combination of a beat and raised outlook is typically positive for the stock.
🍭 Bonus (B): 0/10 β€” Help Supply Services

πŸ” Screening Criteria Changelog β†’

Back to top ↑

🌱 ESG/SRI Exclusions

The following categories are excluded from our screening universe (with a few whitelisted exceptions):

Back to top ↑

Get Daily Advanced Signals Free

Actionable and freshly screened US πŸ‡ΊπŸ‡Έ stocks in your inbox every trading day.

Your subscription could not be saved. Please try again.
Your subscription has been successful.